{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:47:11Z","timestamp":1782740831499,"version":"3.54.5"},"reference-count":18,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"unspecified","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007777","name":"Biocon","doi-asserted-by":"publisher","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}],"id":[{"id":"10.13039\/100007777","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2026,6,18]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the safety, efficacy and immunogenicity of biosimilar aflibercept (MYL-1701P) in participants with diabetic macular oedema who completed the 52-week global phase III trial and were enrolled in an extension study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a 20-week, multicentre, open-label extension study at 15 sites in India, safety and efficacy were assessed in 52 participants who received three doses (2\u2009mg intravitreal) of MYL-1701P either continuing on MYL-1701P (continuation arm) or switching to it from reference aflibercept (switch arm). The primary outcome was safety, assessed by the incidence of treatment-emergent adverse events (TEAEs). The secondary outcome was efficacy and included change in visual acuity (best corrected visual acuity (BCVA) based on Early Treatment Diabetic Retinopathy Study (ETDRS) letters) and central subfield thickness ((CST); by spectral-domain optical coherence tomography).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 52 participants enrolled, 46 completed week 76. Participants in both arms had comparable baseline characteristics. Incident TEAEs were noted in 9\/29 participants in the continuation arm and 7\/23 in the switch arm. No participant reported treatment-induced or boosted antidrug antibodies. The adjusted mean difference in BCVA change between baseline of parent study and week 76 (end of extension study) was \u22121.20 (2.95) ETDRS letters (90%\u2009CI \u22126.15 to 3.75) and from baseline of extension study to week 20 (week 76\u2014parent study) was 1.59 (1.1) (90%\u2009CI \u22120.26 to 3.43). The adjusted mean difference in CST from baseline of parent study to week 76 was \u221215.9 (38.07) \u00b5m (90%\u2009CI \u221280.47 to 48.62) and from baseline of extension study to its end was 13.53 (16.13) \u00b5m (90%\u2009CI \u221213.86 to 40.92).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study had certain limitations, including participation from one geographical area, an open-label design and small number of participants. Despite the limited number of exposures in the switch arm, it still constituted a reasonable exposure, and similar safety, efficacy and immunogenicity profiles were observed between those who continued receiving MYL-1701P and those who switched from reference aflibercept to MYL-1701P in the 20-week extension study of the pivotal trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04674800\">NCT04674800<\/jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03610646\">NCT03610646<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2025-002637","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:05:18Z","timestamp":1782738318000},"page":"e002637","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of biosimilar aflibercept MYL-1701P in diabetic macular oedema: 20-week extension results following the INSIGHT pivotal trial"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct04674800","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03610646","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03610646","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04674800","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rohan","family":"Chauhan","sequence":"first","affiliation":[{"name":"Rising Retina Clinic, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishali","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sribhargava","family":"Natesh","sequence":"additional","affiliation":[{"name":"Vitreoretina, Nethra Eye Hospital, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajpal","family":"Vohra","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, All India Institute of Medical Sciences New Delhi, New Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virendra","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Dr Virendra Laser and Phaco Surgery Center, Jaipur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanna C","family":"Ganapathi","sequence":"additional","affiliation":[{"name":"Clinical Development, Viatris India, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debdipta","family":"Bose","sequence":"additional","affiliation":[{"name":"Clinical Development, Viatris India, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7186-0049","authenticated-orcid":false,"given":"Subramanian","family":"Loganathan","sequence":"additional","affiliation":[{"name":"Clinical Development and Medical Affairs, Biocon Biologics Limited, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"2026062906050876000_11.2.e002637.1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1909"},{"key":"2026062906050876000_11.2.e002637.2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000320075","article-title":"Diabetic macular edema","volume":"47","author":"Bandello","year":"2010","journal-title":"Dev Ophthalmol"},{"key":"2026062906050876000_11.2.e002637.3","unstructured":"International Diabetes Federation . IDF Diabetes Atlas.11th edn. Brussels, 2025. Available: https:\/\/diabetesatlas.org\/media\/uploads\/sites\/3\/2025\/04\/IDF_Atlas_11th_Edition_2025.pdf"},{"key":"2026062906050876000_11.2.e002637.4","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/09286586.2017.1290257","article-title":"Incidence and progression of diabetic retinopathy in urban India: Sankara Nethralaya-Diabetic Retinopathy Epidemiology and Molecular Genetics Study (SN-DREAMS II), report 1","volume":"24","author":"Raman","year":"2017","journal-title":"Ophthalmic Epidemiol"},{"key":"2026062906050876000_11.2.e002637.5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/09286586.2021.1907846","article-title":"Optical coherence tomography-based prevalence of diabetic macular edema and its associated risk factors in urban South India: a population-based study","volume":"29","author":"Pradhana","year":"2022","journal-title":"Ophthalmic Epidemiol"},{"key":"2026062906050876000_11.2.e002637.6","unstructured":"Regeneron Pharmaceuticals . Eylea US prescribing information. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125387lbl.pdf [Accessed 7 Jul 2025]."},{"key":"2026062906050876000_11.2.e002637.7","unstructured":"European Medicines Agency . Eylea summary of product characteristics. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eylea-epar-product-information_en.pdf [Accessed 7 Jul 2025]."},{"key":"2026062906050876000_11.2.e002637.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414264"},{"key":"2026062906050876000_11.2.e002637.9","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis","volume":"6","author":"Virgili","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2026062906050876000_11.2.e002637.10","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jamaophthalmol.2024.3458","article-title":"Aflibercept biosimilar MYL-1701P versus reference aflibercept in diabetic macular edema: the INSIGHT randomised clinical trial","volume":"142","author":"Bressler","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"2026062906050876000_11.2.e002637.11","unstructured":"US Food and Drug Administration . FDA approves first interchangeable biosimilars to Eylea to treat macular degeneration and other eye conditions, Available: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-interchangeable-biosimilars-eylea-treatmacular-degeneration-and-other-eye [Accessed 7 Jul 2025]."},{"key":"2026062906050876000_11.2.e002637.12","unstructured":"International Diabetes Federation . Diabetes facts and figures. 2025. Available: https:\/\/idf.org\/about-diabetes\/diabetes-facts-figures [Accessed 18 Mar 2026]."},{"key":"2026062906050876000_11.2.e002637.13","unstructured":"IDF Atlas . Clinical practice recommendations for managing diabetic macular edema. 2025. Available: https:\/\/idf.org\/about-diabetes\/resources\/idf-clinical-practice-recommendations-for-managing-dme [Accessed 18 Mar 2026]."},{"key":"2026062906050876000_11.2.e002637.14","unstructured":"European Medicines Agency . Yesafili. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/yesafili [Accessed 8 Jul 2025]."},{"key":"2026062906050876000_11.2.e002637.15","unstructured":"US Food and Drug Administration . Approval letter for aflibercept biosimilar. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2024\/761274Orig1s000ltr.pdf [Accessed 25 Sep 2025]."},{"key":"2026062906050876000_11.2.e002637.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2023-001561","article-title":"Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial","volume":"8","author":"Sadda","year":"2023","journal-title":"BMJ Open Ophth"},{"key":"2026062906050876000_11.2.e002637.17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.oret.2025.07.015","article-title":"Randomized trial of biosimilar ABP 938 compared with reference aflibercept in adults with neovascular age-related macular degeneration","volume":"10","author":"Friedman","year":"2026","journal-title":"Ophthalmol Retina"},{"key":"2026062906050876000_11.2.e002637.18","unstructured":"European Medicines Agency . Eyluxvi: EPAR product information. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eyluxvi-epar-product-information_en.pdf [Accessed 18 Mar 2026]."}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2025-002637","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:05:34Z","timestamp":1782738334000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2025-002637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,29]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/bmjophth-2025-002637"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2025-002637","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}